Day One Biopharmaceuticals

Biotech · Acquired

cancer therapeutics developed through rapid drug discovery and development

Claim this profile

Follows are private to you and power your alerts

Updated · dayonebio.com

Sector
Biotech
Total capital
$26K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
$26K
1 award · Veterans Affairs
Rank in Biotech#365 of 4373
Granted patents
1
15 pending · first 2024
Rank in peer group#481 of 1449

Capital timeline

2025FEDERAL ↑EQUITY ↓Cumulative $26K$26K
2025FEDERAL ↑EQUITY ↓Cumulative $26K$26K

Latest events

  • Federal contractVeterans Affairs · Tovorafenib 100MG TAB,PKT,1X6 Ojemda$26K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#481 · top 33%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 1 granted of 16
  • PendingRaf Kinase Inhibitors For Treating Tumors Harboring Gene FusionsUSPTOApplication 18696942
  • GrantedMethod For Producing Optically Active CompoundUSPTOUS 12,129,249
  • PendingCombination Of Raf Inhibitor And Mek InhibitorUSPTOApplication 18450638
Show all 16 patent records
  • Raf Kinase Inhibitors For Treating Tumors Harboring Gene FusionsNov 28, 2024 · Application 18696942Pending
  • Method For Producing Optically Active CompoundOct 29, 2024 · US 12,129,249Granted
  • Combination Of Raf Inhibitor And Mek InhibitorFeb 22, 2024 · Application 18450638Pending
  • Oral Liquid Suspension Of Pan-raf Kinase InhibitorFeb 8, 2024 · Application 18332906Pending
  • Solid Dispersion Of Pan-raf Kinase InhibitorDec 22, 2022 · Application 17824237Pending
  • Combination Of Raf Inhibitors And TaxanesOct 8, 2020 · Application 16889408Pending
  • Oral Liquid Suspension Of Pan-raf Kinase InhibitorApplication PCTUS2023022430Pending
  • Raf Kinase Inhibitors For Treating Tumors Harboring Gene FusionsApplication PCTUS2022045454Pending
  • Methods Of Treating Pediatric Low-grade GliomaApplication 63599378Pending
  • Oral Liquid Suspension Of Pan-raf Kinase InhibitorApplication 63342533Pending
  • Combination Of Raf Inhibitor And Mek InhibitorApplication PCTUS2022016962Pending
  • Raf Kinase Inhibitors For Treating Tumors Harboring Gene FusionsApplication 63251445Pending
  • Methods Of Treating Pediatric Low-grade GliomaApplication 63637875Pending
  • Combination Of Raf Inhibitor And Mek InhibitorApplication 63151425Pending
  • Solid Dispersion Of Pan-raf Kinase InhibitorApplication PCTUS2020062307Pending
  • Methods Of Treating Pediatric Low-grade GliomaApplication PCTUS2024055945Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .